blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3171891

EP3171891 - METHOD [Right-click to bookmark this link]
StatusExamination is in progress
Status updated on  17.08.2019
Database last updated on 20.07.2024
FormerRequest for examination was made
Status updated on  28.04.2017
FormerThe international publication has been made
Status updated on  11.02.2017
Most recent event   Tooltip10.07.2024New entry: Reply to examination report 
Applicant(s)For all designated states
Hansa Biopharma AB
Box 785
220 07 Lund / SE
[N/P]
Former [2019/46]For all designated states
Hansa Bipopharma AB
Box 785
220 07 Lund / SE
Former [2017/22]For all designated states
Hansa Medical AB
P.O. Box 785
220 07 Lund / SE
Inventor(s)01 / KJELLMAN, Christian
c/o Hansa Medical AB
PO Box 785
SE 220 07 Lund / SE
02 / JARNUM, Sofia
c/o Hansa Medical AB
PO Box 785
SE 220 07 Lund / SE
03 / WINSTEDT, Lena
c/o Hansa Medical AB
PO Box 785
SE 220 07 Lund / SE
 [2017/22]
Representative(s)J A Kemp LLP
80 Turnmill Street
London EC1M 5QU / GB
[N/P]
Former [2017/22]Lewis, Graham Matthew
J A Kemp
14 South Square
Gray's Inn
London WC1R 5JJ / GB
Application number, filing date15756845.210.07.2015
[2017/22]
WO2015EP65895
Priority number, dateGB2014001324025.07.2014         Original published format: GB 201413240
[2017/22]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2016012285
Date:28.01.2016
Language:EN
[2016/04]
Type: A2 Application without search report 
No.:EP3171891
Date:31.05.2017
Language:EN
The application published by WIPO in one of the EPO official languages on 28.01.2016 takes the place of the publication of the European patent application.
[2017/22]
Search report(s)International search report - published on:EP14.04.2016
ClassificationIPC:A61K39/395, C12N9/24
[2017/22]
CPC:
A61K38/4873 (EP,IL,KR,US); C12N9/52 (EP,IL,KR,US); A61K35/22 (IL,US);
A61K38/47 (KR); A61K39/395 (IL,US); A61P35/00 (EP,IL,KR);
A61P35/02 (EP,IL); A61P37/06 (EP,IL); A61P43/00 (EP,IL);
C07K14/195 (KR); C07K14/315 (KR); C07K14/34 (KR);
C07K16/00 (EP,IL,US); C12N9/24 (IL); C12N9/2402 (EP,IL,KR,US);
C12Y302/01096 (EP,IL,US); G01N33/686 (IL); A61K2039/505 (IL);
A61K2039/545 (IL); C07K2317/21 (EP,IL,US); C07K2317/52 (EP,IL,US);
C07K2317/54 (EP,IL,US); Y02P20/582 (EP,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/22]
TitleGerman:VERFAHREN[2017/22]
English:METHOD[2017/22]
French:PROCÉDÉ[2017/22]
Entry into regional phase10.02.2017National basic fee paid 
10.02.2017Designation fee(s) paid 
10.02.2017Examination fee paid 
Examination procedure10.02.2017Examination requested  [2017/22]
10.02.2017Date on which the examining division has become responsible
15.09.2017Amendment by applicant (claims and/or description)
21.08.2019Despatch of a communication from the examining division (Time limit: M06)
26.02.2020Reply to a communication from the examining division
06.11.2020Despatch of a communication from the examining division (Time limit: M06)
13.05.2021Reply to a communication from the examining division
13.03.2024Despatch of a communication from the examining division (Time limit: M04)
10.07.2024Reply to a communication from the examining division
Fees paidRenewal fee
12.07.2017Renewal fee patent year 03
11.07.2018Renewal fee patent year 04
15.07.2019Renewal fee patent year 05
14.07.2020Renewal fee patent year 06
15.07.2021Renewal fee patent year 07
15.06.2022Renewal fee patent year 08
14.06.2023Renewal fee patent year 09
30.05.2024Renewal fee patent year 10
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[Y]WO2008071418  (HANSA MEDICAL AB, et al) [Y] 10-12 * page 36, last paragraph *;
 [I]WO2009033670  (GENOVIS AB [SE], et al) [I] 19-23 * claims 16, 18, 20 *;
 [I]WO2013037824  (GENOVIS AB [SE], et al) [I] 19-23 * page 27, [2], pages 30-34;; claim 22 *;
 [XYI]WO2013110946  (CRISPIN MATTHEW DAVID MAX [GB], et al) [X] 1-9,13 * example 3;; claims 1-20 * [Y] 10-12 [I] 14-18;
 [IY]  - KAVITHA BARUAH ET AL, "Selective Deactivation of Serum IgG: A General Strategy for the Enhancement of Monoclonal Antibody Receptor Interactions", JOURNAL OF MOLECULAR BIOLOGY, ACADEMIC PRESS, UNITED KINGDOM, vol. 420, no. 1, doi:10.1016/J.JMB.2012.04.002, ISSN 0022-2836, (20120403), pages 1 - 7, (20120405), XP028514772 [I] 1-9,13-18 * abstract * [Y] 10-12

DOI:   http://dx.doi.org/10.1016/j.jmb.2012.04.002
 [IY]  - KUTTY SELVA NANDAKUMAR ET AL, "Blocking of experimental arthritis by cleavage of IgG antibodies in vivo", ARTHRITIS & RHEUMATISM, (20070101), vol. 56, no. 10, doi:10.1002/art.22930, ISSN 0004-3591, pages 3253 - 3260, XP055107646 [I] 1-9,13-18 * page 3258 - page 3259; figures 1-6 * * abstract * [Y] 10-12,22,23

DOI:   http://dx.doi.org/10.1002/art.22930
 [A]  - ALBERT HEIKE ET AL, "In vivo enzymatic modulation of IgG glycosylation inhibits autoimmune disease in an IgG subclass-dependent manner", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, vol. 105, no. 39, doi:10.1073/PNAS.0808248105, ISSN 0027-8424, (20080930), pages 15005 - 15009, (20080924), XP002569095 [A] 1-18 * abstract *

DOI:   http://dx.doi.org/10.1073/PNAS.0808248105
 [I]  - Jenny Johansson Söderberg, "The streptococcal IgG degrading enzyme IdeS -studies on host-pathogen interactions", (20120101), URL: https://www.diva-portal.org/smash/get/diva2:513947/FULLTEXT01.pdf, (20160208), XP055248265 [I] 19-23 * figure 4 *
 [XY]  - Anonymous, "Structural Biochemistry/Proteins/Enzyme-Linked Immunoabsorbent Assay (ELISA) - Wikibooks, open books for an open world", (20121029), URL: https://en.wikibooks.org/wiki/Structural_Biochemistry/Proteins/Enzyme-Linked_Immunoabsorbent_Assay_(ELISA), (20160209), XP055248514 [X] 19-21 * the whole document * [Y] 22,23
by applicantUS4366241
    - ACKERMAN, M.E.; B. MOLDT; R.T. WYATT; A.S. DUGAST; E. MCANDREW; S. TSOUKAS; S. JOST; C.T. BERGER; G. SCIARANGHELLA; Q. LIU, "A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples", JIMMUNOL METHODS, (2011), vol. 366, pages 8 - 19
    - AGNISWAMY, J.; B. LEI; J.M. MUSSER; P.D. SUN, "Insight of host immune evasion mediated by two variants of group a Streptococcus Mac protein", JBIOL CHEM, (2004), vol. 279, pages 52789 - 52796
    - BREZSKI, R.J.; O. VAFA; D. PETRONE; S.H. TAM; G. POWERS; M.H. RYAN; J.L. LUONGO; A. OBERHOLTZER; D.M. KNIGHT; R.E. JORDAN, "Tumor-associated and microbial proteases compromise host IgG effector functions by a single cleavage proximal to the hinge", PROC NATL ACAD SCI U SA, (2009), vol. 106, pages 17864 - 17869
    - CARAPETIS, J.R.; A.C. STEER; E.K. MULHOLLAND; M. WEBER., "The global burden of group A streptococcal diseases", LANCET INFECT DIS, (2005), vol. 5, pages 685 - 694
    - COLLEN, D.; F. DE COCK; E. DEMARSIN; S. JENNE; I. LASTERS; Y. LAROCHE; P. WARMERDAM; L. JESPERS, "Recombinant staphylokinase variants with altered immunoreactivity. III: Species variability of antibody binding patterns", CIRCULATION, (1997), vol. 95, pages 455 - 462
    - DECLERCK, P.J.; S. VANDERSCHUEREN; J. BILLIET; H. MOREAU; D. COLLEN, "Prevalence and induction of circulating antibodies against recombinant staphylokinase", THROMB HAEMOST, (1994), vol. 71, pages 129 - 133
    - "Plasmapheresis", ISMAIL, N.; R. NEYRA; R. HAKIM, Handbook of dialysis, (2001), pages 231 - 262
    - JOHANSSON, B.P.; O. SHANNON; L. BJORCK, "IdeS: a bacterial proteolytic enzyme with therapeutic potential", PLOS ONE, (2008), vol. 3, page E1692
    - JORDAN, S.C.; D. TYAN; D. STABLEIN; M. MCINTOSH; S. ROSE; A. VO; M. TOYODA; C. DAVIS; R. SHAPIRO; D. ADEY, "Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial.", JAM SOC NEPHROL, (2004), vol. 15, pages 3256 - 3262
    - KARLSSON, C.; L. MALMSTROM; R. AEBERSOLD; J. MALMSTROM, "Proteome-wide selected reaction monitoring assays for the human pathogen Streptococcus pyogenes", NAT COMMUN, (2012), vol. 3, page 1301
    - MACLEAN, B.; D.M. TOMAZELA; N. SHULMAN; M. CHAMBERS; G.L. FINNEY; B. FREWEN; R. KERN; D.L. TABB; D.C. LIEBLER; M.J. MACCOSS, "Skyline: an open source document editor for creating and analyzing targeted proteomics experiments", BIOINFORMATICS, (2010), vol. 26, pages 966 - 968
    - MAINET, D.; M. DEL ROSARIO; A. TORUNCHA; P. PRATS; C. VALENZUELA; P. LOPEZ SAURA, "Similar, more than 6-months persisted, antibody and neutralizing activity responses in patients with acute myocardial infarction treated with recombinant or natural streptokinase", FIBRINOLYSIS PROTEOL, (1998), vol. 12, pages 301 - 309
    - MONTGOMERY, R.A.; A.A. ZACHARY; L.C. RACUSEN; M.S. LEFFELL; K.E. KING; J. BURDICK; W.R. MALEY; L.E. RATNER, "Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients", TRANSPLANTATION, (2000), vol. 70, pages 887 - 895
    - NANDAKUMAR, K.S.; B.P. JOHANSSON; L. BJORCK; R. HOLMDAHL, "Blocking of experimental arthritis by cleavage of IgG antibodies in vivo", ARTHRITIS RHEUM, (2007), vol. 56, pages 3253 - 3260
    - OJO, A.O.; R.A. WOLFE; P.J. HELD; F.K. PORT; R.L. SCHMOUDER, "Delayed graft function: risk factors and implications for renal allograft survival", TRANSPLANTATION, (1997), vol. 63, pages 968 - 974
    - RYAN, M.H.; D. PETRONE; J.F. NEMETH; E. BARNATHAN; L. BJORCK; R.E. JORDAN, "Proteolysis of purified IgGs by human and bacterial enzymes in vitro and the detection of specific proteolytic fragments of endogenous IgG in rheumatoid synovial fluid", MOL IMMUNOL, (2008), vol. 45, pages 1837 - 1846
    - TELEMAN, J.; S. WALDEMARSON; J. MALMSTROM; F. LEVANDER, "Automated quality control system for LC-SRM setups", JPROTEOMICS, (2013), vol. 95, pages 77 - 83
    - TRADTRANTIP, L.; N. ASAVAPANUMAS; A.S. VERKMAN, "Therapeutic cleavage of anti-aquaporin-4 autoantibody in neuromyelitis optica by an IgG-selective proteinase", MOL PHARMACOL, (2013), vol. 83, pages 1268 - 1275
    - WENIG, K.; L. CHATWELL; U. VON PAWEL-RAMMINGEN; L. BJORCK; R. HUBER; P. SONDERMANN, "Structure of the streptococcal endopeptidase IdeS, a cysteine proteinase with strict specificity for IgG", PROC NATL ACAD SCI USA, (2004), vol. 101, pages 17371 - 17376
    - VINCENTS, B.; U. VON PAWEL-RAMMINGEN; L. BJORCK; M. ABRAHAMSON, "Enzymatic characterization of the streptococcal endopeptidase, IdeS, reveals that it is a cysteine protease with strict specificity for IgG cleavage due to exosite binding", BIOCHEMISTRY, (2004), vol. 43, pages 15540 - 15549
    - VINDEBRO, R.; C. SPOERRY; U. VON PAWEL-RAMMINGEN, "Rapid IgG heavy chain cleavage by the streptococcal IgG endopeptidase IdeS is mediated by IdeS monomers and is not due to enzyme dimerization", FEBS LETT, (2013), vol. 587, pages 1818 - 1822
    - VO, A.A.; M. LUKOVSKY; M. TOYODA; J. WANG; N.L. REINSMOEN; C.H. LAI; A. PENG; R. VILLICANA; S.C. JORDAN, "Rituximab and intravenous immune globulin for desensitization during renal transplantation", N ENGL J MED, (2008), vol. 359, pages 242 - 251
    - VO, A.A.; E.A. WECHSLER; J. WANG; A. PENG; M. TOYODA; M. LUKOVSKY, N. REINSMOEN; S.C. JORDAN, "Analysis of subcutaneous (SQ) alemtuzumab induction therapy in highly sensitized patients desensitized with IVIG and rituximab", AM J TRANSPLANT, (2008), vol. 8, pages 144 - 149
    - VON PAWEL-RAMMINGEN, U.; B.P. JOHANSSON; L. BJORCK, "IdeS, a novel streptococcal cysteine proteinase with unique specificity for immunoglobulin G.", EMBO J, (2002), vol. 21, pages 1607 - 1615
    - VON PAWEL-RAMMINGEN, U.; B.P. JOHANSSON; H. TAPPER; L. BJORCK, "Streptococcus pyogenes and phagocytic killing", NAT MED, (2002), vol. 8, pages 1044 - 1045
    - YANG, R.; M.A. OTTEN; T. HELLMARK; M. COLLIN; L. BJORCK; M.H. ZHAO; M.R. DAHA; M. SEGELMARK., "Successful treatment of experimental glomerulonephritis with IdeS and EndoS, IgG-degrading streptococcal enzymes", NEPHROL DIAL TRANSPLANT, (2010), vol. 25, pages 2479 - 2486
    - AKESSON, P.; M. RASMUSSEN; E. MASCINI; U. VON PAWEL-RAMMINGEN; R. JANULCZYK; M. COLLIN; A. OLSEN; E. MATTSSON; M.L. OLSSON; L. BJO, "Low antibody levels against cell wall-attached proteins of Streptococcus pyogenes predispose for severe invasive disease", J INFECT DIS, (2004), vol. 189, pages 797 - 804
    - DING JW; ZHOU T; ZENG H; MA L; VERBEEK JS; YIN D, "m.fl. Hyperacute rejection by anti-Gal IgGl, IgG2a, and IgG2b is dependent on complement and Fc-gamma receptors", J IMMUNOL., (20080101), vol. 180, no. 1, pages 261 - 8
    - JORDAN SC; VO A; BUNNAPRADIST S; TOYODA M; PENG A; PULIYANDA D; KAMIL E; TYAN D, "Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients", TRANSPLANTATION, (200308), vol. 76, no. 4, pages 631 - 636
    - MOLL S; PASCUAL M, "Humoral rejection of organ allografts", AM. J. TRANSPLANT, (200511), vol. 5, pages 2611 - 2618
    - MONTGOMERY RA; HARDY MA; JORDAN SC; RACUSEN LC; RATNER LE; TYAN DB; ZACHARY AA, "Consensus opinion from the antibody working group on the diagnosis, reporting, and risk assessment for antibody-mediated rejection and desensitization protocols", TRANSPLANTATION, (200407), vol. 78, no. 2, pages 181 - 185
    - THOMAS B. MARTINS, DEVELOPMENT OF INTERNAL CONTROLS FOR THE LUMINEX INSTRUMENT AS PART OF A MULTIPLEX SEVEN-ANALYTE VIRAL RESPIRATORY ANTIBODY PROFILE
    - PATEL R; TERASAKI PI, "Significance of the positive crossmatch test in kidney transplantatio", N. ENGL. J. MED., (196904), vol. 280, no. 14, pages 735 - 739
    - PIERSON RN 3RD., "Antibody-mediated xenograft injury: mechanisms and protective strategies", TRANSPL IMMUNOL, (200906), vol. 21, no. 2, pages 65 - 9
    - TERASAKI PI; OZAWA M, "Predicting kidney graft failure by HLA antibodies: a prospective trial", AM. J. TRANSPLANT, (200403), vol. 4, no. 3, pages 438 - 443
    - VO AA; PETROZZINO J; YEUNG K; SINHA A; KAHWAJI J; PENG A, "m.fl. Efficacy, outcomes, and cost-effectiveness of desensitization using IVIG and rituximab", TRANSPLANTATION, (20130327), vol. 95, no. 6, pages 852 - 8
    - VON PAWEL-RAMMINGEN U; JOHANSSON BP; BJORCK L, "IdeS, a novel streptococcal cysteine proteinase with unique specificity for immunoglobulin G", EMBO J, (200204), vol. 21, no. 7, pages 1607 - 1615
    - AKESSON P; MORITZ L; TRUEDSSON M, CHRISTENSSON B; VON PAWEL-RAMMINGEN U, "IdeS, a highly specific immunoglobulin G (IgG)-cleaving enzyme from Streptococcus pyogenes, is inhibited by specific IgG antibodies generated during infection", INFECT. IMMUN, (200601), vol. 74, no. 1, pages 497 - 503
    - AVALOS A. M.; PLOEGH H., "Early BCR Events and Antigen Capture, Processing and Loading on MHC Class II on B cells", FRONT. IMMUNOL., (201403), vol. 10, no. 5, page 92
    - DAL PORTO JM; GAULD SB; MERRELL KT; MILLS D; PUGH-BERNARD AE; CAMBIER J., "B cell antigen receptor signaling 101", MOL. IMMUNOL., (2004), vol. 41, no. 6-7, pages 599 - 613
    - DOBBS AK; YANG T; FARMER D; KAGER L; PAROLINI O; CONLEY ME., "Cutting edge: a hypomorphic mutation in Igbeta (CD79b) in a patient with immunodeficiency and a leaky defect in B cell development", J IMMUNOL., (20061215), vol. 179, no. 4, pages 2055 - 9
    - HARDY I; ANCERIZ N; ROUSSEAU F; SEEFELDT M; IRLA M ET AL., "Anti-CD79 Antibody Induces B Cell Anergy That Protects against Autoimmunity", J IMMUNOL., (2014), vol. 192, pages 1641 - 1650
    - JAHNMATZ M; KESA G; NETTERLID E; BUISMAN AM; THORSTENSSON R ET AL., "Optimization of a human IgG B-cell ELISpot assay for the analysis of vaccine-induced B-cell responses", J IMMUNOL METHODS, (2013), vol. 391, pages 50 - 59
    - JOHANSSON BP; SHANNON O; BJORCK L, "IdeS: a bacterial proteolytic enzyme with therapeutic potential", PLOS ONE, (2008), vol. 3, page EL692
    - JOHNSON GL; LAPADAT R, "Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases", SCIENCE, (2002), vol. 298, pages 1911 - 1912
    - KUROSAKI T, "Regulation of B-cell signal transduction by adaptor proteins", NAT. REV. IMMUNOL., (2002), vol. 2, no. 5, pages 354 - 363
    - LANZAVECCHIA A, "Receptor-mediated antigen uptake and its effect on antigen presentation to class II-restricted T lymphocytes", ANNU REV IMMUNOL, (1990), vol. 8, pages 773 - 93
    - MANZ R; HAUSER A; HIEPE F; RADBRUCH A., "Maintenance Of Serum Antibody Levels", ANNU. REV. IMMUNOL., (2005), vol. 23, pages 367 - 86
    - NANDAKUMAR KS; JOHANSSON BP; BJORCK L; HOLMDAHL R, "Blocking of experimental arthritis by cleavage of IgG antibodies in vivo", ARTHRITIS RHEUM, (2007), vol. 56, pages 3253 - 3260
    - RAJEWSKY K., "Clonal selection and learning in the antibody system", NATURE, (1996), vol. 381, no. 6585, pages 751 - 8
    - RETH M, "Antigen receptor tail clue", NATURE, (1989), vol. 338, no. 6214, pages 383 - 384
    - RETH M; WIENANDS J, "Initiation and processing of signals from the B cell antigen receptor", ANNU. REV. IMMUNOL., (1997), vol. 15, pages 453 - 479
    - SCHARENBERG AM; HUMPHRIES LA; RAWLINGS DJ, "Calcium signalling and cell-fate choice in B cells", NAT. REV. IMMUNOL, (2007), vol. 7, no. 10, pages 778 - 789
    - STUART G. TANGYE; KIM L., "Good Human IgM+CD27+ B Cells: Memory B Cells or ''Memory'' B Cells?", THE JOURNAL O/1MMUNO/OGV, (2007), vol. 179, pages 13 - 19
    - SU YF; CHUANG WJ; WANG SM; CHEN WY; CHIANG-NI C; LIN YS; WU JJ; LIU CC, "The deficient cleavage of M protein-bound IgG by IdeS: insight into the escape of Streptococcus pyogenes from antibody-mediated immunity", MOL IMMUNOL., (2011), vol. 49, no. 1-2, pages 134 - 42
    - TANGYE; TRALINGTON, "Memory B cells: Effectors of long-lived immune responses", EUR. J. IMMUNOL., (2009), vol. 39, pages 2065 - 2075
    - TRADTRANTIP L; ASAVAPANUMAS N; VERKMAN AS, "Therapeutic cleavage of anti-aquaporin-4 autoantibody in neuromyelitis optica by an IgG-selective proteinase", MOL PHARMACOL, (2013), vol. 83, pages 1268 - 1275
    - VINCENTS B; VON PAWEL-RAMMINGEN U; BJORCK L; ABRAHAMSON M, "Enzymatic characterization of the streptococcal endopeptidase, IdeS, reveals that it is a cysteine protease with strict specificity for IgG cleavage due to exosite binding", BIOCHEMISTRY, (2004), vol. 43, pages 15540 - 9
    - VON PAWEL-RAMMINGEN U; JOHANSSON B P; BJORCK L, "IdeS, a novel streptococcal cysteine proteinase with unique specificity for immunoglobulin G", EMBO J, (2002), vol. 21, pages 1607 - 15
    - WENIG K; CHATWELL L; VON PAWEL-RAMMINGEN U; BJORCK L; HUBER R; SONDERMANN P, "Structure of the streptococcal endopeptidase IdeS, a cysteine proteinase with strict specificity for IgG", PROC NATL ACAD SCI USA, (2004), vol. 101, pages 17371 - 6
    - YANG R; OTTEN MA; HELLMARK T; COLLIN M; BJORCK L ET AL., "Successful treatment of experimental glomerulonephritis with IdeS and EndoS, IgG-degrading streptococcal enzymes", NEPHROL DIAL TRANSPLANT, (2010), vol. 25, pages 2479 - 2486
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.